Last reviewed · How we verify
SG
SG is an adenosine 2A receptor antagonist that blocks immunosuppressive signaling in the tumor microenvironment to enhance anti-tumor immunity.
SG is an adenosine 2A receptor antagonist that blocks immunosuppressive signaling in the tumor microenvironment to enhance anti-tumor immunity. Used for Advanced or metastatic solid tumors (in combination with checkpoint inhibitors).
At a glance
| Generic name | SG |
|---|---|
| Also known as | Trodelvy |
| Sponsor | Arcus Biosciences, Inc. |
| Drug class | Adenosine 2A receptor antagonist |
| Target | A2A receptor (adenosine 2A receptor) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Adenosine accumulates in tumors and suppresses T cell function through A2A receptor signaling. By blocking A2A receptors, SG (also known as AB928) prevents adenosine-mediated immunosuppression, allowing T cells to mount a more effective anti-tumor response. This mechanism is often combined with checkpoint inhibitors like PD-1/PD-L1 inhibitors to further enhance immune activation.
Approved indications
- Advanced or metastatic solid tumors (in combination with checkpoint inhibitors)
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Immune-related adverse events
Key clinical trials
- Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer (PHASE1, PHASE2)
- Study of Sacituzumab Tirumotecan Combined With Toripalimab for Resectable Stage II-IIIB NSCLC (PHASE2)
- Dry Needling for Temporomandibular Disorder (NA)
- Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (PHASE3)
- Study of Novel Treatment Combinations in Patients With Lung Cancer (PHASE2)
- Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread (PHASE2)
- Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer (PHASE1)
- Stool Analysis After Sleeve Gastrectomy vs Gastric Bypass
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SG CI brief — competitive landscape report
- SG updates RSS · CI watch RSS
- Arcus Biosciences, Inc. portfolio CI